目的 检测血管内皮生长因子（VEGF）、白细胞分化抗原34（CD34）及CXC趋化因子受体4（CXCR4）在转移性鼻咽癌患者鼻咽部肿瘤组织中的表达，探讨它们与鼻咽癌各种临床病理因素的关系以及它们之间的相互联系。 方法 采用免疫组织化学链霉素抗生物素蛋白-过氧化物酶连结法检测2003年3月－2009年5月35例转移性鼻咽癌患者VEGF、CD34及CXCR4在鼻咽部肿瘤组织中的表达情况，结合患者临床病理特征进行分析。 结果 转移性鼻咽癌患者鼻咽部肿瘤组织中的VEGF及CXCR4阳性表达率分别为62.9%（22∕35）和42.9%（15∕35），CD34计数为11～92，平均43.2 ± 20.5。无肺转移较有肺转移的患者VEGF的阳性表达率高（78.9%、43.8%，P=0.043），多器官转移较单器官转移的患者CXCR4的表达强度高（62.5%、26.3%，P=0.044）。 结论 VEGF表达阳性的患者易发生肺转移；CXCR4强表达的患者易发生多器官转移。
ObjectiveTo investigate the effects of migration and expression from chemokine receptor 4 (chemokine receptor-4, CXCR4) of rat bone marrow mesenchymal stem cells (BMSCs) which were pretreated by atorvastatin (ATV) in vitro.MethodsIsolated, cultivated, identified the BMSCs, pretreated P4-P6 of BMSCs with different concentrations of ATV for 12 hours. The experimental group was divided into control group, 0.1 nM/L (group 0.1 nM), 1 nM/L (1 nM group), 10 nM/L (10 nM group), 100 nM/L (100 nM group), 1 000 nM/L (1 000 nM group). The mRNA and protein of CXCR4 were determined by real time-polymerase chain reaction and Western blot. Immunofluoreseence assay were used to detect the expression levels of CXCR4. The migration ability of BMSCs were measured by transwell chamber.ResultsImmunofluoreseence assay showed the protein level of CXCR4 of group 1 nM and 10 nM were significantly higher than the other group. RT-PCR and Western blot showed the protein and mRNA level of CXCR4 in 10 nM was higher than that in group 1 nM. The migration ability of group 10 nM was higher than 1 nM and control group.ConclusionsATV can be dose-dependent promote expression levels of CXCR4 of BMSCs cultivated in vitro.